Akcea Therapeutics, Inc.
If you purchased Akcea Therapeutics, Inc. securities and would like to join the action, please click "Join This Action" below.
AKCEA MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE SALE OF AKCEA THERAPEUTICS, INC. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – AKCA
September 3, 2020.
New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Akcea Therapeutics, Inc. (NASDAQ: AKCA) to Ionis Pharmaceuticals, Inc. for $18.15 per share is fair to Akcea shareholders. On behalf of Akcea shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
The investigation concerns whether Akcea and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to: (1) obtain the best possible consideration for Akcea shareholders; (2) determine whether Ionis is underpaying for Akcea; and (3) disclose all material information necessary for Akcea shareholders to adequately assess and value the proposed transaction.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.